Alexandros Poutoglidis

Dr. Alexandros Poutoglidis


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 August 2021 in Cureus
Verified
Journal Article
Open access
NTNikolaos Tsetsos
Nikolaos Tsetsos
APAlexandros Poutoglidis
Alexandros Poutoglidis
KVKonstantinos Vlachtsis
Konstantinos Vlachtsis
AKAdamantios Kilmpasanis
Adamantios Kilmpasanis
SGSpyridon Gougousis
Spyridon Gougousis
Sudden sensorineural hearing loss (SSHL) is a common otolaryngology emergency that significantly affects the patient’s quality of life. Although in most cases its etiology remains unknown (idiopathic SSHL), viral infections and vascular compromise constitute the most widely accepted etiopathogenic mechanisms. Specifically, occlusion of the internal auditory artery has been reported in cases of sudden deafness. Thrombotic events following the Oxford-AstraZeneca COVID-19 vaccine are rare. There have been reports of SSHL following immunization with Pfizer and Moderna COVID-19 vaccine; however, no etiologic relationship has been established between the two entities yet. We present a unique case of SSHL following the second dose of the Oxford-AstraZeneca COVID-19 vaccine. A 61-year-old female was referred to our department with a four-day history of the right-sided sense of fulness combined with almost complete hearing loss that had started two days after the second dose of Oxford-AstraZeneca COVID-19 vaccine. Pure tone audiometry showed profound right-sided sensorineural hearing loss. Magnetic resonance imaging of the brain and internal auditory canal and magnetic resonance angiography were both normal. The combination of glucocorticoids and acetylsalicylic acid leads to almost full recovery 15 days after deafness. The COVID-19 era is full of new challenges and clinical dilemmas. In our case, the addition of acetylosalicid acid to the patient’s initial treatment may have contributed to the hearing restoration; however, this fact will remain a hypothesis.

30 January 2022 in Cureus
Verified
Journal Article
Open access
SKStergiani Keramari
Stergiani Keramari
APAlexandros Poutoglidis
Alexandros Poutoglidis
SCStefanos Chatzis
Stefanos Chatzis
MKMichael Keramaris
Michael Keramaris
Christos SavopoulosChristos Savopoulos
Christos Savopoulos
CKChristos Kaiafa
Christos Kaiafa
Parvovirus B19 (B19V) infection may lead to myocarditis, a life-threatening condition in pediatric patients. In this review, we aim to present published pediatric cases of B19V-associated myocarditis in order to understand the deep complex connections and draw useful conclusions. We performed a comprehensive search of MEDLINE, Science Direct, and Google Scholar electronic databases. A total of 32 cases were included in our study. The most common presenting symptom was tachycardia in 22/32 patients (68.7%), followed by tachypnoea (21/32, 65.6%), fever, and rash (12/32, 37.5% for both of them). Cardiac arrest, loss of consciousness, and systemic infection were associated with the worst prognosis, with statistically significant differences (p-value 0.001, 0.02, 0.001. respectively). A percentage as high as 90.4% of patients with left ventricular (LV) dysfunction and reduced ejection fraction (EF) were discharged. Twelve patients required ventilatory support, five required extracorporeal membrane oxygenation (ECMO), and three underwent heart surgery. Treatment with immunosuppressive agents and immunoglobulin was found to be beneficial for patients (p-value 0.006 and 0.004, respectively). In conclusion, B19V myocarditis has high mortality rates in children. There is no specific antiviral treatment for B19V infection and therapeutic strategies for myocarditis aim to delay the worsening of heart failure and to preserve the LV function. Inotropic drugs, diuresis, ventilatory support, Intravenous immunoglobulin (IVIG), and immunosuppressive therapy seem to help the recovery of the myocardium in children with LV dilation, dysfunction, and reduced EF. Children with cardiac arrest, arrhythmias, and loss of consciousness have the worst prognosis.

19 April 2022 in European Archives of Oto-Rhino-Laryngology
Verified
Journal Article
Closed access
PDF file
CVChrysoula Vardaxi
Chrysoula Vardaxi
NTNikolaos Tsetsos
Nikolaos Tsetsos
AKAikaterini Koliastasi
Aikaterini Koliastasi
APAlexandros Poutoglidis
Alexandros Poutoglidis
KSKonstantinos Sapalidis
Konstantinos Sapalidis
Athanasia PrintzaAthanasia Printza
Athanasia Printza

26 February 2022 in Ear, Nose & Throat Journal
Verified
Journal Article
Open access
APAlexandros Poutoglidis
Alexandros Poutoglidis
NTNikolaos Tsetsos
Nikolaos Tsetsos
PKParaskevi Karamitsou
Paraskevi Karamitsou
EFEvropi Forozidou
Evropi Forozidou
Konstantinos GarefisKonstantinos Garefis
Konstantinos Garefis
KVKonstantinos Vlachtsis
Konstantinos Vlachtsis

10 December 2020 in Otolaryngologia Polska
Verified
Journal Article
Closed access
APAlexandros Poutoglidis
Alexandros Poutoglidis
NTNikolaos Tsetsos
Nikolaos Tsetsos
SSSotiria Sotiroudi
Sotiria Sotiroudi
GFGeorgios Fyrmpas
Georgios Fyrmpas
FPFrideriki Poutoglidou
Frideriki Poutoglidou
KVKonstantinos Vlachtsis
Konstantinos Vlachtsis
Introduction: Parotid gland neoplasms represent a heterogenous group of tumors, either benign or malignant. The diagnosis and management of parotid gland tumors is complicated by their relative infrequency and their diverse biologic behavior. Aim: The aim of this study is to investigate the epidemiological characteristics, the recurrence rates and the surgical approach employed for parotid gland tumors in Northern Greece. Material and methods: This is a single-center retrospective study. All patients admitted to the ENT department of "G. Papanikolaou" General Hospital of Thessaloniki from January 2012 to June 2019 with the diagnosis of parotid gland tumor were included in the study. Patients with incomplete charts and patients that underwent revision surgeries were excluded. Chi-squared tests were used to assess the associations between variables. Results: A total of 207 patients with a mean age of 54.97 (range 16-91) were included in the study. Benign neoplasms accounted for 87.9% of the cases. Warthin's tumor was the most common neoplasm encountered, with an incidence of 46.8%, followed by pleomorphic adenoma (31.9%). There was a higher incidence of parotid gland tumors in males and smokers (P = 0.025, P = 0.001 respectively). The majority of the patients were treated with an extracapsular resection (60.4%) or with a partial superficial parotidectomy (22.6%). In 12 cases (5.7%), there was a recurrence of the lesion. The most common complications encountered were facial nerve injury, Frey's syndrome and hematoma formation. Conclusions: Parotid gland tumors are typically benign, non-aggressive tumors, more frequently seen in men than women. There is a positive association between smoking and parotid gland tumor development. Comprehensive information regarding recurrence and complication rates is presented.

7 June 2022 in Journal of Neurological Surgery Part B: Skull Base
Verified
Journal Article
Closed access
PDF file
NTNikolaos Tsetsos
Nikolaos Tsetsos
APAlexandros Poutoglidis
Alexandros Poutoglidis
DTDimitrios Terzakis
Dimitrios Terzakis
IEIoannis Epitropou
Ioannis Epitropou
AOAmanda Oostra
Amanda Oostra
Christos GeorgalasChristos Georgalas
Christos Georgalas
Objective Nasal cavity and paranasal sinuses host a variety of malignant tumors with adenoid cystic carcinoma (ACC) being the most frequent cancer of salivary gland origin. The histological origin of such tumors virtually precludes primarily intracranial localization. The aim of this study is to report cases of primarily intracranial ACC without evidence of other primary lesions at the end of an exhaustive diagnostic workup. Methods An electronic medical record search complemented by manual searching was conducted to identify prospective and retrospective cases of intracranial ACCs treated in Endoscopic Skull Base Centre Athens at the Hygeia Hospital, Athens from 2010 until 2021 with a mean follow-up time of at least 3 years. Patients were included if after complete diagnostic workup there was no evidence of a nasal or paranasal sinus primary lesion and extension of the ACC. All patients were treated with a combination of endoscopic surgeries performed by the senior author followed by radiotherapy (RT) and/or chemotherapy. Results Three unique illustrative cases (ACC involving the clivus, cavernous sinus and pterygopalatine fossa, one orbital ACC with pterygopalatine fossa and cavernous sinus involvement and one involving cavernous sinus, and Meckel's cave with extension to the foramen rotundum) were identified. All patients underwent subsequently proton or carbon-ion beam radiation therapy. Conclusions Primary intracranial ACCs constitute an extremely rare clinical entity with atypical presentation, challenging diagnostic workup and management. The design of an international web-based database with a detailed report of these tumors would be extremely helpful.